November 19, 2021Open Access

Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity

HCHyeree ChoiThe Wistar Institute MHMichelle HoThe Wistar Institute OAOpeyemi S. AdenijiCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Key Points

Key points are not available for this paper at this time.

Abstract

testing utilizing ovarian cancer humanized mouse model showed a drastic reduction in tumor volume. Together, we developed novel antibodies that augment anti-tumor immunity through interference with Siglec-9-mediated immunosuppression.

Perguntar à IA

Bookmark

View Full Paper

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Choi et al. (Fri,) studied this question.

synapsesocial.com/papers/6a0514746c3d07813971bdbd https://doi.org/https://doi.org/10.3389/fonc.2021.778989

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

2019 · 322 citations